Completed PHASE3 INTERVENTIONAL 2-arm NCT03389724

Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia

Sponsor: Children's Cancer Hospital Egypt 57357

Conditions Acute Myeloid Leukemia in Children Bone Tumor Cardiotoxicity

Interventions Capoten®

Updated 10 times since 2018 Last updated: Nov 7, 2022 Started: Nov 14, 2017 Primary completion: Nov 1, 2021 Completion: Nov 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Acute Myeloid Leukemia in Children and Bone Tumor and is currently completed. Children's Cancer Hospital Egypt 57357 leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2022 — Jul 2024 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Sep 2021 — Dec 2022 [monthly]

Recruiting PHASE3
Feb 2021 — Sep 2021 [monthly]

Recruiting PHASE3

▶ Show 5 earlier versions

Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Apr 2019 — Aug 2020 [monthly]

Recruiting PHASE3
Jun 2018 — Apr 2019 [monthly]

Recruiting PHASE3
Jan 2018 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Cancer Hospital Egypt 57357

Data source: Children's Cancer Hospital Egypt 57357

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt